

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS II LLC
Petitioner

v.

NPS PHARMACEUTICALS, INC.
Patent Owner

Case IPR2015-01093
Patent 7,056,886

PATENT OWNER'S UPDATED EXHIBIT LIST

TABLE OF EXHIBITS

Ex. No.	Description
2001	NPS Pharmaceuticals, Inc.'s Requests for Production to Petitioner
2002	NPS Pharmaceuticals, Inc.'s Interrogatories to Petitioner
2003	NPS Pharmaceuticals, Inc.'s Topics for Examination of Petitioner
2004	General Hedge Fund Structure & Regulation
2005	RPI Diagram
2006	Form ADV Brochure of HCM (Mar. 30, 2015)
2007	Form ADV of HCM (Mar. 30, 2015)
2008	Annual Report of HCM (July 8, 2013)
2009	Amended Form D of HCOP (May 12, 2014)
2010	Amended Form D of HCP (May 12, 2014)
2011	Credes Onshore Form D (Jan. 14, 2015)
2012	Credes Onshore Delaware Secretary of State Website Printout
2013	HCMF Cayman Islands Search Report
2014	Credes Offshore Form D (Jan. 14, 2015)
2015	Credes Offshore Caymans Search Report
2016	Form D of HOF (April 9, 2015)
2017	Certificate of Formation of IPNav (Nov. 13, 2007)
2018	Certificate of Formation of nXnP (Sept. 24, 2014)
2019	Ed Silverman, <i>Innovate or Else: Kyle Bass Strikes Again and Challenges Shire Patents</i> , <u>Wall Street Journal</u> (April 2, 2015)
2020	Robert Cyran, <i>Kyle Bass Wields New Weapon in Challenging Drug Makers</i> , <u>The New York Times</u> (February 11, 2015)
2021	Joseph Walker and Rob Copeland, <i>New Hedge Fund Strategy: Dispute the Patent, Short the Stock</i> , <u>Wall Street Journal</u> (April 7, 2015)
2022	Julia La Roche, <i>Hedge Fund Manager Kyle Bass is Going After Big Pharma and Its "BS Patents,"</i> <u>Business Insider</u> (Jan. 7, 2015)
2023	Julia La Roche, <i>Hedge Fund Manager Kyle Bass is Going After Big Pharma and Its "BS Patents,"</i> <u>Business Insider Australia</u> (Jan. 8, 2015)
2024	Delaware Secretary of State Business Entity Search Printout for Coalition Entities
2025	Cayman Islands Search Report of HOM
2026	Cayman Islands Search Report of HOF
2027	GATTEX® Product Label
2028	Lehninger <i>et al.</i> , <i>Principles of Biochemistry</i> , 2 nd ed., Chapters 5-7 & 18, pp. 111-197 & 542-597 (1993)

Ex. No.	Description
2029	Voet and Voet, Biochemistry, 2 nd ed., Chapters 7 & 14, pp. 141-90 & 371-410 (1995)
2030	Purves <i>et al.</i> , Life: The Science of Biology, 3 rd ed., Ch. 3, pp. 40-59 (1992)
2031	NPS Pharmaceuticals, Inc. Form10-K 2014
2032	Email from Jeff Blake to Counsel for Patent Owner
2033	Declaration of Christopher E. Kirkpatrick
2034	Declaration of Erich Spangenberg
2035	The Wall Street Journal – New Hedge Fund Strategy: Challenge the Patent, Short the Stock
2036	The Wall Street Journal – Innovate or Else: Kyle Bass Strikes Again and Challenges Shire Patents
2037	Hayman Capital Management, L.P. Form ADV Part 2A Brochure
2038	Brubaker and Drucker, Structure-Function of the Glucagon Receptor Family of G-Protein Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors, Receptors and Channels, vol. 8, pp. 179-188 (2002)
2039	Chaturvedi, A Report on Stability of Polypeptides and Proteins, Birla Institute of Technology and Science Pilani (Rajasthan) (August 2009)
2040	Vassilatis <i>et al.</i> , “The G protein-coupled receptor repertoires of human and mouse”, <i>Proc Natl Acad Sci USA</i> 100 (8): 4903–4908 (2003)
2041	Declaration of Gordon Rausser, Ph.D. Under 37 C.F.R. § 1.68 in Support of Patent Owner’s Response to the Petition
2042	Transcript of Video Deposition of Anthony Palmieri III, Ph.D.
2043	CV of John F. Carpenter, Ph.D.
2044	CV of Gordon Rausser, Ph.D.
2045	Jackson <i>et al.</i> , “Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas,” <i>Curr. Diab. Rep.</i> 12(6) Dec. 2012 705-710.
2046	Onoue <i>et al.</i> , “Mishandling of therapeutic Peptide Glucagon Generates Amyloidogenic Fibrils,” <i>Pharm. Res.</i> 21(7) July 2004
2047	U.S. Pharmacopeia 24, 774-77 (1999)
2048	Joshi <i>et al.</i> , “The degradation pathways of Glucagon in Acidic Solutions,” <i>Int’l J. Pharmaceutics</i> , 203(1-2) August 2000 115-125, Abstract; Fang <i>et al.</i> , “Effects of Excipients on the Chemical and Physical Stability of Glucagon during Freeze-Drying and Storage in Dried Formulations,” <i>Pharm. Res.</i> 29:3278-3291 (2012)
2049	Fang <i>et al.</i> , Effects of Excipients on the Chemical and Physical Stability of Glucagon during Freeze-Drying and Storage in Dried Formulations, <i>Pharm.</i>

Ex. No.	Description
	Res. 29:3278-3291 (2012)
2050	Blundell, "The Conformation of Glucagon," Handbook of Experimental Pharmacology, vol. 66, 37-56 (1983)
2051	Boesch et al., " ¹ H Nuclear-Magnetic-Resonance Studies of the Molecular Conformation of Monomeric Glucagon in Aqueous Solution," Eur. J. Biochem., 91, 209-214 (1978)
2052	Akers, "Excipient-Drug Interactions in Parenteral Formulations", Journal of Pharmaceutical Sciences, Vol. 91, No. 11, November 2002
2053	U.S. Pharmacopeia 788, "Particulate Matter In Injections", The United States Pharmacopeial Convention (2011)
2054	Remington's Pharmaceutical Sciences, 18 th Ed., 1549-51 (1990)
2055	U.S. Patent Publication No. 2013/0310314
2056	Process Validation and/or Evaluation for Gattex
2057	Annex1 Summary of Product Characteristics
2058	Orange Book Listing for Gattex
2059	Eli Lilly & Co., "Glucagon for Injection (rDNA Origin)" (2012)
2060	Al-Hussein et al., "Investigation of Histidine Stabilizing Effects on LDH During Freeze-Drying", Journal of Pharmaceutical Sciences, Vol. 102, No. 3 (2013)
2061	Izutsu et al., "Freeze-Drying of Proteins in Glass Solids Formed by Basic Amino Acids and Dicarboxylic Acids", Chem. Pharm. Bull. 57(1), 43-48 (2009)
2062	U.S. Pharmacopeia 23, 1650-51 (1995)
2063	Center for Drug Evaluation and Research, Application Number:203441Orig1s000, Chemistry Review(s)
2064	U.S. Food and Drug Administration, "FDA Approved Drug Products — Zorbitive." Accessed January 19, 2016 at https://www.accessdata.fda.gov
2065	Shire, "Shire completes acquisition of NPS Pharma," February 21, 2015
2066	Engellenner, Tom, "Bass Goes Fishing: Trouble Ahead for Pharma, Or For Hedge-Fund Trolls?" <i>Forbes</i> July 15, 2015
2067	Walker, Joseph and Rob Copeland, "New Hedge Fund Strategy: Dispute the Patent, Short the Stock," <i>Wall Street Journal</i> April 7, 2015
2068	Wieczner, Jen, "Why Drug Price Controversy Is Great News for this Hedge Fund Manager," <i>Fortune</i> September 30, 2015
2069	Buchman, Alan, "Etiology and Initial Management of Short Bowel Syndrome," <i>Gastroenterology</i> 130, no. 2 (2006): S5-S15
2070	Pirona, Loris, et al., "Espen endorsed recommendations. Definition and

Ex. No.	Description
	classification of intestinal failure in adults,” <i>Journal of Clinical Nutrition</i> 34 (2015):171–180
2071	O’Keefe, Stephen, “Short Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview,” <i>Clinical Gastroenterology and Hepatology</i> 4, no. 1 (2006): 6–10
2072	Buchman, Alan, “The Clinical Management of Short Bowel Syndrome: Steps to Avoid Parenteral Nutrition,” <i>Nutrition</i> 13, no. 10 (1997): 907–913
2073	NPS, “Developing orphan products for patients with rare gastrointestinal and endocrine disorders,” August 2012
2074	Hofstetter, Steven, Lee Stern and Jacob Willet, “Key issues in addressing the clinical and humanistic burden of short bowel syndrome in the US,” <i>Current Medical Research and Opinion</i> 29, no. 5 (2013)
2075	Shire, “Gattex Physician ATU Final Report,” October 22, 2015
2076	O’Keefe, Stephen, “Nutritional Issues in the Short Bowel Syndrome – Total Parenteral Nutrition, Enteral Nutrition and the Role of Transplantation,” <i>Nestle Nutrition Institute Workshop Series</i> 82 (2015): 75–90
2077	Tee, Cheng, Katharina Wallis and Simon Gabe, “Emerging Treatment Options for Short Bowel Syndrome: Potential Role of Teduglutide,” <i>Clinical and Experimental Gastroenterology</i> 4 (2011): 189–196
2078	Naberhuis, Jane and Kelly Tappenden, “Teduglutide for Safe Reduction of Parenteral Nutrient And/or Fluid Requirements in Adults: A Systematic Review,” <i>Journal of Parenteral and Enteral Nutrition</i> (2015)
2079	Buchman, Alan, “Teduglutide and Short Bowel Syndrome: Every Night without Parenteral Fluids Is a Good Night,” <i>Gastroenterology</i> 143, no. 6 (October 2012): 1416–1420
2080	U.S. Food and Drug Administration, “FDA Approved Drug Products — Zorbitive.” Accessed January 19, 2016 at https://www.accessdata.fda.gov .
2081	Crohn’s and Colitis Foundation of America, “Short Bowel Syndrome and Crohn’s Disease,” July 2013
2082	Donohoe, Claire and John Reynolds, “Short Bowel Syndrome,” <i>The Surgeon</i> 8 (2010): 270–279
2083	U.S. Food and Drug Administration, “Zorbitive — somatropin (rDNA origin) for injection,” December 1, 2003
2084	Wales, P., et al., “Human Growth Hormone and Glutamine for Patients with Short Bowel Syndrome (Review),” <i>The Cochrane Library</i> , 6 (2010): 1–30, p. 2 (“Wales (2010)”)
2085	Serono 2005 Annual Report

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.